Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Cipla
McKesson
Fuji
Deloitte
UBS
Cantor Fitzgerald
Federal Trade Commission
QuintilesIMS

Generated: October 21, 2018

DrugPatentWatch Database Preview

XARTEMIS XR Drug Profile

« Back to Dashboard

Which patents cover Xartemis Xr, and what generic alternatives are available?

Xartemis Xr is a drug marketed by Mallinckrodt Inc and is included in one NDA. There are thirteen patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in XARTEMIS XR is acetaminophen; oxycodone hydrochloride. There are sixty-six drug master file entries for this compound. Fifty-three suppliers are listed for this compound. Additional details are available on the acetaminophen; oxycodone hydrochloride profile page.

Drug patent expirations by year for XARTEMIS XR
Pharmacology for XARTEMIS XR
Drug ClassOpioid Agonist
Mechanism of ActionFull Opioid Agonists
Synonyms for XARTEMIS XR
731850-86-5
Acetaminophen / oxycodone hydrochloride
Acetaminophen and oxycodone hydrochloride
Acetaminophen mixture with oxycodone hydrochloride
DTXSID40223433
LS-187810
SCHEMBL2516628

US Patents and Regulatory Information for XARTEMIS XR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mallinckrodt Inc XARTEMIS XR acetaminophen; oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 204031-001 Mar 11, 2014 DISCN Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Mallinckrodt Inc XARTEMIS XR acetaminophen; oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 204031-001 Mar 11, 2014 DISCN Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Mallinckrodt Inc XARTEMIS XR acetaminophen; oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 204031-001 Mar 11, 2014 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Mallinckrodt Inc XARTEMIS XR acetaminophen; oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 204031-001 Mar 11, 2014 DISCN Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for XARTEMIS XR
Drugname Dosage Strength RLD Date
➤ Subscribe Extended-release Tablets 7.5 mg/325 mg ➤ Subscribe ➤ Sign Up

Premature patent expiration for: XARTEMIS XR

Expiration due to failure to pay maintenance fee

Patent Number Tradename Expiration Date
➤ Sign Up XARTEMIS XR ➤ Sign Up

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Cipla
McKesson
Fuji
Deloitte
UBS
Cantor Fitzgerald
Federal Trade Commission
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.